RICHMOND, Va.--(BUSINESS WIRE)--Commonwealth Biotechnologies, Inc. (CBI, CBTE.OB) today announced the appointment of Richard J. Freer, Ph.D. as Chief Executive Officer (CEO). He replaces Dr. Bill Guo who has served as Acting CEO since January of 2009.
Dr. Freer, one of the founders of the company, has served at various times as its Chairman of the Board, Director of Compliance, and most recently as Chief Operating Officer. In addition to his new position as CEO, Dr. Freer sits on the Board of Directors. “These are difficult times for the company but I look forward to working with the Board to restore shareholder value to the best of my ability,” said Dr. Freer.
CBI offers cutting-edge research and development products and services to the global life sciences industry. CBI now operates solely through Mimotopes Pty Ltd, Melbourne, Australia, a peptide and discovery chemistry business.
Forward Looking Statements
No statement made in this press release should be interpreted as an offer to purchase any security. Such an offer can only be made in accordance with the Securities Act of 1933, as amended and applicable state securities laws. Any statements contained in this release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties as identified in CBI’s filings with the Securities and Exchange Commission. Actual results, events or performance may differ materially. Readers are cautioned not to place undo reliance on these forward-looking statements, which speak only as the date hereof. Further, all forward-looking statements included in this press release are based upon information available to CBI as of the date hereof. CBI assumes no obligation to update any such forward-looking statements.
Commonwealth Biotechnologies, Inc. (CBI)
Richard J Freer, Ph.D., CEO